Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Covalon TechnologiesTSXV:COV 84 Return-on-Tangible-Equity is 16.89% as of Mar. 2026, which is 128% above its 10-year median of 7.42. GuruFocus rates TSXV:COV with a GF Score™ of 84/100 and a GF Value™ of C$2.17 (Fairly Valued). The stock has 2 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Covalon Technologies ranks better than 54.49% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Covalon Technologies's annualized net income for the quarter that ended in Mar. 2026 was C$4.37 Mil. Covalon Technologies's average shareholder tangible equity for the quarter that ended in Mar. 2026 was C$25.89 Mil. Therefore, Covalon Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 16.89%.
The historical rank and industry rank for Covalon Technologies's Return-on-Tangible-Equity or its related term are showing as below:
TSXV:COV'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -160.29 Med: 7.42 Max: 177.76
Current: 5.89
During the past 13 years, Covalon Technologies's highest Return-on-Tangible-Equity was 177.76%. The lowest was -160.29%. And the median was 7.42%.
TSXV:COV's Return-on-Tangible-Equity is ranked better than 54.49% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs TSXV:COV: 5.89
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Covalon Technologies Return-on-Tangible-Equity Related Terms
Covalon Technologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:COV vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.89% mean?
Covalon Technologies (TSXV:COV) has a Return-on-Tangible-Equity of 16.89% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Covalon Technologies and its competitors. This is 128% above median its historical median of 7.42. According to the industry distribution chart, Covalon Technologies ranks #345 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 45.5%.
Is Covalon Technologies' Return-on-Tangible-Equity too high?
Covalon Technologies' current Return-on-Tangible-Equity of 16.89% is 128% above median its 10-year median of 7.42. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. Covalon Technologies' value of 16.89% is 316.5% above this industry median. Based on the distribution chart, Covalon Technologies ranks #345 out of 758 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #345 out of 758 companies for Return-on-Tangible-Equity. This puts Covalon Technologies in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.06. Covalon Technologies' value of 16.89% is 316.5% above this benchmark. While the company's 10-year median is 7.42 vs. the industry median of 4.06, Covalon Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Return-on-Tangible-Equity of 16.89% is 316.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Return-on-Tangible-Equity is 16.89%, which is 128% above median its own 10-year median of 7.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (TSXV:COV) is currently considered Fairly Valued. The stock's GF Value™ is C$2.17, compared to a current price of C$2.24 — trading 3.2% above its estimated fair value. The current Return-on-Tangible-Equity is 16.89%, which is 128% above median its 10-year median of 7.42 and 316.5% above the Medical Devices & Instruments industry median of 4.06. Covalon Technologies' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Covalon Technologies (TSXV:COV), the current Return-on-Tangible-Equity is 16.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (TSXV:COV) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be overvalued.
The current stock price of C$2.24 is trading 3.2% above its estimated GF Value™ of C$2.17.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for TSXV:COV:
Return-on-Tangible-Equity: 16.89% (128% above median its 10-year median of 7.42)
GF Value™: C$2.17 vs. price of C$2.24 (3.2% above fair value)
Industry Position: 316.5% above the Medical Devices & Instruments median (#345 of 758)
No single metric tells the full story. See the TSXV:COV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
84GF Score
Get the complete analysis for TSXV:COV
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:COV has been successfully added to your 
